FW: [asid-ozbug] duodenoscopes/ ERCP and microbiological surveillance to assess reprocessing

[Michael Wishart]

[Cross-posted from OzBug, with permission Moderator]
NB Please respond directly to Dr Kainer as ouitlined in the email, not back to the list. Thanks.
——– Original message ——–
From: Marion Kainer
Date:10/10/2014 08:36 (GMT+10:00)
To: “‘asid-ozbug@burnet.edu.au'”
Subject: [asid-ozbug] duodenoscopes/ ERCP and microbiological surveillance to assess reprocessing
Dear colleagues:
Several outbreaks of carbapenem-resistant Enterobacteriaceae have been reported in the United States that were associated with the use of a duodenoscope for which no breaches in reprocessing were identified. One of these outbreaks was reported in this weeks JAMA: http://jama.jamanetwork.com/article.aspx?articleid=1911326
The U.S. Centers for Disease Control and Prevention is interested in learning more about the experiences of healthcare facilities in other countries that routinely perform microbiological surveillance of duodenoscopes to assess adequacy of reprocessing. If your facility routinely performs microbiologic surveillance of duodenoscopes, we would appreciate it if you could please answer the following questions and send them to Marion Kainer ( marion.kainer@tn.gov) I will compile the results and forward to CDC. If there is interest, I can provide summary results to this list-serv as well:
1. How frequently does your facility culture duodenoscopes to assess adequacy of reprocessing (e.g., every time a duodenoscope is reprocessed, at least weekly, etc.)?
2. Are duodenoscope cultures usually processed (assess for microbial growth) by the laboratory that your facility regularly uses or are they sent to a special laboratory for processing?
3. On average, what percentage of cultures obtained from reprocessed duodenoscopes at your facility are found to have microbial growth?

4. Are duodenoscopes at your facility usually quarantined (held from use) until culture results are available?

5. How has microbiological surveillance of duodenoscopes adversely impacted your facilitys practice (e.g., led to delays in performing procedures, required purchasing additional duodenoscopes for use, etc.)?

6. How has microbiological surveillance of duodenoscopes positively impacted your facilitys practice?

7. Any other comments that you would like to provide.

Many thanks in advance for taking the time to respond!
Best,
Marion

Marion Kainer MBBS MPH FRACP FSHEA
Director, Healthcare Associated Infections and Antimicrobial Resistance Program
Tennessee Department of Health
Tel: +1 615 741 7247; Fax: +1 615 741 3857; email: marion.kainer@tn.gov

______________________________________________________________________
For the purposes of protecting the integrity and security of the SVHA network and the information held on it, all emails to and from any email address on the svha.org.au domain (or any other domain of St Vincents Health Australia Limited or any of its related bodies corporate) (an SVHA Email Address) will pass through and be scanned by the Symantec.cloud anti virus and anti spam filter service. These services may be provided by Symantec from locations outside of Australia and, if so, this will involve any email you send to or receive from an SVHA Email Address being sent to and scanned in those locations.

MESSAGES POSTED TO THIS LIST ARE SOLELY THE OPINION OF THE AUTHOR, AND DO NOT REPRESENT THE OPINION OF ACIPC.

The use of trade/product/commercial brand names through the list is discouraged by ACIPC. If you wish to discuss specific reference to products or services by brand or commercial names, please do this outside the list.

Archive of all messages are available at http://aicalist.org.au/archives – registration and login required.

Replies to this message will be directed back to the list. To create a new message send an email to aicalist@aicalist.org.au

To send a message to the list administrator send an email to aicalist-request@aicalist.org.au.

You can unsubscribe from this list be sending ‘signoff aicalis

[Author]

Posts